{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-001397","form_type":"8-K","ticker":"SNWV","cik":"0001417663","company_name":"SANUWAVE Health, Inc.","filed_at":"2025-01-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.575602+00:00","generated_at":"2026-05-28T01:52:15.033852+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sanuwave announces preliminary Q4 2024 revenue of $10.1-10.3M, record high, up 44-47% YoY","bullets":["Q4 2024 revenue expected $10.1-10.3M, highest quarterly revenue in company history; increase of 44-47% YoY.","UltraMist revenue up >54% vs Q4 2023, representing ~98% of total Q4 revenue; applicator sales all-time record ~58% of total.","Full year 2024 preliminary revenue $32.4-32.6M, up 59-60% vs 2023.","CEO Morgan Frank cites third consecutive record quarter and 'breakout year' targeting rapid profitable growth.","Company expects to release complete Q4 and FY2024 results in March 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-001397","json":"https://secwatch.observer/filing/0001628280-25-001397.json","markdown":"https://secwatch.observer/filing/0001628280-25-001397.md","text":"https://secwatch.observer/filing/0001628280-25-001397.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1417663/000162828025001397/0001628280-25-001397-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1417663/000162828025001397/snwv-20250113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T01:52:15.033852+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}